Geburtshilfe und Frauenheilkunde, Table of Contents Geburtshilfe Frauenheilkd 2024; 84(10): 915-916DOI: 10.1055/a-2369-7654 DGGG Stellungnahme – Ungeplante „Ozempic-Babys“ als „Nebeneffekt“ der Adipositastherapie Statement zu GLP-1-Analoga präkonzeptionell und in der Schwangerschaft Ute Schäfer-Graf Recommend Article Abstract Buy Article Full Text References Literatur 1 Cena H, Chiovato L, Nappi RE. Obesity, Polycystic Ovary Syndrome, and Infertility: A New Avenue for GLP-1 Receptor Agonists. J Clin Endocrinol Metab 2020; 105: e2695-e2709 2 Ma R, Ding X, Wang Y. et al. The therapeutic effects of glucagon-like peptide-1 receptor agonists and metformin on polycystic ovary syndrome: A protocol for systematic review and meta-analysis. Medicine (Baltimore) 2021; 100: e26295 3 Cesta CE, Rotem R, Bateman BT. et al. Safety of GLP-1 Receptor Agonists and Other Second-Line Antidiabetics in Early Pregnancy. JAMA Intern Med 2024; 184: 144-152 4 Muller DRP, Stenvers DJ, Malekzadeh A. et al. Effects of GLP-1 agonists and SGLT2 inhibitors during pregnancy and lactation on offspring outcomes: a systematic review of the evidence. Front. Endocrinol 2023; 14: 1215356
